Gilva Therapeutics, INC.
No. 18, Siyuan St., Zhongzheng Dist., Taipei City 100047 ,
Taiwan (R.O.C.) (Room 909 of Complex for Research Excellence)
Registration No.：89114272
TEL：+886 2 33661914
FAX：+886 2 23652804
INTRODUCTION
Gilva is a biopharmaceutical company focused on the development of small molecule drugs for unmet medical needs, especially in rare diseases.
Gilva has a robust drug discovery and development platform. This platform effectively optimizes the efficacy, druggability or safety of drugs based on the structure-activity relationship (SAR). Gilva also has a team with extensive experience in drug development, which can improve the efficiency of drug discovery and reduce development risks.
PIPELINE
GV-100
GV-100 is an oral selective HDAC6 inhibitor. HDAC6 interacts with various substrate proteins, regulating numerous cell physiological or pathological mechanisms. It exerts functions such as anti-inflammatory, anti-fibrotic, and cytoprotective effects by modulating post-translational modifications of crucial proteins within cells. HDAC6 is also overexpressed in ADPKD, fibrotic diseases, neurodegenerative disorders, and cancers, highlighting its significant role in various diseases.
NEWS
Gilva Therapeutics’GV-100 Phase 1 Clinical Trial Application Approved in Australia
Gilva Therapeutics Collaborates with National Taiwan University to Publish First-Generation HDAC6 Inhibitors for ADPKD in the Journal of Medicinal Chemistry
2026/1/12 Forward Asset Management Inc. has resigned as a Board director of Gilva Therapeutics INC., and one replacement director will be appointed to fill the resulting vacancy.